CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
November 21st 2024
Aerobic exercise improved self-reported cognitive function in women undergoing chemotherapy for breast cancer but had no effect on objective cognitive function.
Managing Adverse Events of Breast Cancer with Your Oncology Nurse
March 23rd 2019Debu Tripathy, M.D., the editor in chief of CURE®, recently sat down at the Miami Breast Cancer Conference to discuss the importance of oncology nurses in breast cancer care and offered insight as to how they can keep up-to-date with the constant advancements in the field.
The FDA Approves Fourth Herceptin Biosimilar
March 12th 2019The Food and Drug Administration (FDA) has granted an approval to Trazimera (PF-05280014; trastuzumab-qyyp), a Herceptin (trastuzumab) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.
Dealing with Shoulder Pain After Breast Cancer Treatment
March 9th 2019Breast cancer treatment is a life-saver but also can have side effects, including some related to shoulder pain. It is good to start doing the exercises as soon as the doctor recommends it. After that, a regular tune-up with a physical therapist can help.
FDA Approves Tecentriq Combo for Frontline TNBC
March 8th 2019The Food and Drug Administration has granted an accelerated approval to the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).